Fosun Pharma increases stake in subsidiary, Henlius Biotech

Shanghai Fosun Pharmaceutical Group (SSE:600196) announced it will increase its stake in its controlling subsidiary, Shanghai Henlius Biotech, through an equity transfer agreement. Fosun Pharma will acquire a total of 21,034,313 non-listed shares of Henlius Biotech for HKD 517,444,099.80, representing approximately 3.87% of Henlius Biotech's total share capital. The shares will be acquired at HKD 24.60 per share. Following the transaction, Fosun Pharma's equity stake in Henlius Biotech will increase from 59.56% to 63.43%. The deal involves an associated transaction as one of the sellers, Wuxi Tongshan, is deemed a related party of Fosun Pharma, through a board member connection. The transaction does not constitute a major asset restructuring. The agreement is pending the fulfillment of payment conditions for final settlement.